Related Experiment Video

Updated: Jul 20, 2026

High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum
10:19

High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum

Published on: November 23, 2013

[Autoantibodies to glutamate receptors in children with chronic posttraumatic headache]

A V Goriunova, N A Bazarnaia, E G Sorokina

    Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
    |September 16, 2006
    PubMed

    Insights

    Children with chronic posttraumatic headache after mild head injury show elevated autoantibodies to AMPA and NMDA glutamate receptors, suggesting a link to brain hypoxia and the need for metabolic therapy.

    Area of Science:

    • Neuroscience
    • Immunology
    • Pediatrics

    Background:

    • Chronic posttraumatic headache is a common sequela of mild traumatic brain injury in children.
    • Autoantibodies (aAB) to glutamate receptors may play a role in the pathophysiology of posttraumatic headache.
    • Understanding these mechanisms is crucial for developing effective therapeutic strategies.

    Purpose of the Study:

    • To investigate the levels of autoantibodies (aAB) to AMPA and NMDA glutamate receptors in children with chronic posttraumatic headache following mild skull injury.
    • To correlate autoantibody levels with injury type (concussion vs. contusion) and injury history (single vs. repeated concussion).
    • To explore potential associations between autoantibody levels, EEG findings, and the need for metabolic therapy.

    Main Methods:

    • Serum samples from 60 children (aged 7-16) with chronic posttraumatic headache were analyzed for autoantibodies (aAB) to AMPA (Glu R1) and NMDA (NR 2A) glutamate receptors.
    • Children were grouped based on injury type: concussion (single or repeated) and brain contusion.
    • Autoantibody levels were measured 6 months and 1 year post-injury, expressed as a percentage of control levels, with >120% considered significant. EEG was also performed.

    Main Results:

    • Elevated NMDA receptor aAB levels were observed in the first year post-injury, particularly in children with single concussion (145%±12.6%), brain contusion (165%±34%), and repeated concussion (108%±12.4%).
    • AMPA receptor aAB levels were elevated in children with repeated concussion (150%±16.8%) and brain contusion (167%±31.3%).
    • EEG revealed nonspecific paroxysmal discharges in 18% and epileptiform activity in 6% of children.

    Conclusions:

    • Children experiencing chronic posttraumatic headache after mild head injury exhibit increased autoantibodies to glutamate receptors.
    • Hyperstimulation of these receptors likely reflects underlying hypoxic processes in the brain.
    • These findings support the need for metabolic therapy in managing pediatric posttraumatic headache.

    More Related Videos

    A Simple Cell-based Immunofluorescence Assay to Detect Autoantibody Against the N-Methyl-D-Aspartate (NMDA) Receptor in Blood07:20

    A Simple Cell-based Immunofluorescence Assay to Detect Autoantibody Against the N-Methyl-D-Aspartate (NMDA) Receptor in Blood

    Published on: January 9, 2018

    Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models10:46

    Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models

    Published on: May 3, 2017

    Related Concept Videos

    Antiepileptic Drugs: Glutamate Antagonists01:14

    Antiepileptic Drugs: Glutamate Antagonists

    Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
    Myasthenia Gravis: Diagnostic Tests01:15

    Myasthenia Gravis: Diagnostic Tests

    Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
    The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
    Myasthenia Gravis ll: Pathophysiology01:22

    Myasthenia Gravis ll: Pathophysiology

    The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
    Myasthenia Gravis: Overview and Treatment01:20

    Myasthenia Gravis: Overview and Treatment

    Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
    These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...